바이오벤투스 (BVS) 주가

바이오벤투스(BVS)는 NASDAQ에 상장된 Healthcare · Medical Devices 기업입니다. 현재가 $12.91 (+2.22%), 시가총액 $0.71B, PER (주가수익비율) 25.61, 52주 최저~최고 $6.14 ~ $10.92.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for p

핵심 지표

• 현재가: $12.91 (+2.22%)
• 시가총액: $0.71B
• PER (주가수익비율): 25.61
• 52주 최저~최고: $6.14 ~ $10.92
• 섹터: Healthcare
• 산업: Medical Devices
• 거래소: NASDAQ

바이오벤투스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

바이오벤투스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.3333

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 3.77
• 순이익률: 0.05%
• 영업이익률: 0.07%

자주 묻는 질문